SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions is trending following a recent manufacturing partnership announcement, which has intensified short-squeeze activity driven by its extremely low public float after a recent reverse stock split. The community is actively discussing the stock's significant volatility and potential for further upward momentum, contrasting with some calls for caution. This market dynamic unfolds as the company expands global adoption of its non-invasive fingerprint drug screening technology and navigates the FDA clearance process for the U.S. market.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is actively trending following the FDA approval of NEREUS, marking the first new motion sickness treatment in over 40 years. The community is highly focused on NEREUS's potential to address GLP-1 induced nausea, seeing this as a massive market opportunity and positioning VNDA as a compelling buyout target for larger pharmaceutical companies. This significant regulatory win, alongside a strong pipeline, is driving optimism for substantial future upside.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is generating significant buzz following substantial insider share purchases by Apple CEO and Nike board member Tim Cook and its own CEO, Elliott Hill, signaling strong executive confidence. This activity has sparked a lively debate among investors, with many viewing it as a compelling turnaround story and value opportunity after recent market pressure, while some remain cautious about ongoing challenges and competitive headwinds.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is generating significant buzz, primarily driven by its extremely low public float and high insider ownership, fueling speculation among traders about a potential short squeeze. The community is actively comparing its recent volatility and rapid price movements to other trending SPACs, with discussions often focusing on its merger agreement and aggressive upside potential.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility following the FDA's Complete Response Letter for its relacorilant drug, which cited a need for more efficacy evidence despite the GRACE trial meeting its primary endpoint. This news has sparked a polarized debate, with many investors viewing the substantial stock drop as an overreaction and a prime "bargain biobuy" given the company's strong existing revenue and extensive pipeline. However, others remain cautious, calling it a "total reset" while some attribute parts of the decline to typical end-of-year tax-loss selling.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending after announcing significant new orders for its autonomous systems, bolstering its position in critical defense and infrastructure sectors. The community is expressing strong optimism, amplified by this robust demand and the recent launch of a 2X leveraged ETF, which has increased market visibility. Investors are actively discussing Ondas's expanding leadership in the multi-domain autonomy space, driven by global security needs and strategic growth.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano ($ADA) is trending amidst widespread community frustration over significant price declines and accusations of being a "scam" or "worthless," with many blaming founder Charles Hoskinson for its perceived underperformance. Discussions are heavily focused on substantial investor losses and fears of further "rugpulls" or a broader "crypto doomsday." However, a notable counter-narrative centers around the meme coin $COCK and its "Cocky Wings LLC" actively working to bring real-world revenue and liquidity to the Cardano chain.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

ALCY is capturing significant attention amid a broader "low float SPAC" trend, drawing parallels to recent high-volume movements in similar vehicles. Community sentiment is highly optimistic, anticipating a breakout fueled by its limited share availability and a recent announcement regarding a potential merger with Cartiga, a litigation finance asset management platform. Traders are actively discussing rotational plays and expecting substantial momentum as part of this ongoing SPAC theme.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA granting Priority Review for its AXS-05 treatment for Alzheimer's disease agitation, with an action date anticipated in April, alongside positive updates for its narcolepsy candidate, AXS-12. This pivotal regulatory progress, coupled with strong sales growth for its existing Auvelity product, is driving significant community excitement, as investors anticipate continued pipeline advancements and a potential transition to a higher market valuation. Many believe the company is "killing it" and poised for substantial future gains, celebrating consistent product performance and strategic momentum in the CNS therapeutic space.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing highly polarized community sentiment, with many discussing tax-loss selling influencing its current price action while anticipating a potential rebound. Conversations frequently revolve around "bagholding" frustrations balanced by persistent hopes for significant pumps and a return to higher valuations, often comparing its performance against other meme coins and the trending RAGE.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso

Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.

Top Analyst Reports for Eli Lilly, Shell & ICICI Bank

LLY's strong GLP-1 demand, international launches and new drug contributions highlight why it leads today's top analyst reports lineup.

Vaso Stock Up Following Strong Q3 Earnings and Profit Turnaround

VASO reports a third-quarter 2025 profit turnaround with higher revenue, stronger margins and robust cash flow from subscriptions.

The Zacks Analyst Blog Highlights Roche, Linde, Disney and Vaso

Zacks spotlights Roche, Linde, Disney, and Vaso as analysts weigh drug demand, gas contracts, global expansion, and IT-driven resilience.

Top Analyst Reports for Roche, Linde & Walt Disney

Roche gains from strong drug demand, Linde builds on record orders, while Disney faces TV woes and bets on global growth.

Vaso Stock Down Following Q2 Earnings as Revenue and Margins Fall

VASO reports a second-quarter 2025 loss as lower imaging deliveries and rising costs pressured revenue and profit margins.

The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies

META, NOW, and BKNG lead with AI-driven growth and digital transformation tailwinds, while VASO and BIAF offer speculative upside.

Top Research Reports for Meta Platforms, ServiceNow & Booking

META, NOW, and BKNG gain ground as AI, digital transformation, and global travel trends fuel top-line momentum.

Vaso Stock Slips Post Q1 Earnings Despite Record Revenue Growth

Vaso Corp. engages in the healthcare equipment and information technology industries. It operates through the following segments: Information Technology (IT), Professional Sales Service, and Equipment. The IT segment focuses on healthcare IT and managed network technology services. The Professional Sales Service segment is involved in selling healthcare capital equipment. The Equipment segment consists of designing, manufacturing, selling, and servicing proprietary medical devices. The company was founded by John C. K. Hui and William Cross in July 1987 and is headquartered in Plainview, NY.

VASO
Vaso Corp

Feed

News

Sentiment

Fundamentals

Info

Latest VASO News

VASOVaso Corp